tiprankstipranks
Zealand Pharma (GB:0NZU)
LSE:0NZU
UK Market
0NZU
Zealand Pharma
RESEARCH TOOLSreports

Zealand Pharma (0NZU) Share Forecast & Price Target

18 Followers
See the Price Targets and Ratings of:

0NZU Analyst Ratings

Hold
4Ratings
Hold
1 Buy
3 Hold
0 Sell
Based on 4 analysts giving stock ratings to
Zealand
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0NZU Stock 12 Month Forecast

Average Price Target

kr346.25
▲(13.56% Upside)
Based on 4 Wall Street analysts offering 12 month price targets for Zealand Pharma in the last 3 months. The average price target is kr346.25 with a high forecast of kr435.00 and a low forecast of kr300.00. The average price target represents a 13.56% change from the last price of kr304.90.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"297":"kr297","404":"kr404","511":"kr511","350.5":"kr350.5","457.5":"kr457.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":435,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">kr435.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":346.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">kr346.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":300,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">kr300.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[297,350.5,404,457.5,511],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302,312.2307692307692,322.46153846153845,332.6923076923077,342.9230769230769,353.15384615384613,363.38461538461536,373.61538461538464,383.8461538461538,394.0769230769231,404.30769230769226,414.53846153846155,424.7692307692308,{"y":435,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302,305.40384615384613,308.8076923076923,312.21153846153845,315.61538461538464,319.0192307692308,322.4230769230769,325.8269230769231,329.2307692307692,332.63461538461536,336.03846153846155,339.4423076923077,342.84615384615387,{"y":346.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,302,301.84615384615387,301.6923076923077,301.53846153846155,301.38461538461536,301.2307692307692,301.0769230769231,300.9230769230769,300.7692307692308,300.61538461538464,300.46153846153845,300.3076923076923,300.15384615384613,{"y":300,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":454.028,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":478.502,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":510.024,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":502.13,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":469.8,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":427.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":364.05,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304.79,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.087,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298.245,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Targetkr435.00Average Price Targetkr346.25Lowest Price Targetkr300.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on GB:0NZU
Yihan Li
Barclays
Barclays
kr425→kr330
Hold
8.23%
Upside
Downgraded
09/08/26
Zealand Pharma downgraded to Equal Weight from Overweight at BarclaysZealand Pharma downgraded to Equal Weight from Overweight at Barclays
J.P. Morgan Analyst forecast on GB:0NZU
Sophia Graeff Buhl-Nielsen
J.P. Morgan
J.P. Morgan
kr460→kr435
Buy
42.67%
Upside
Reiterated
08/25/26
Zealand Pharma price target lowered to DKK 435 from DKK 460 at JPMorganZealand Pharma price target lowered to DKK 435 from DKK 460 at JPMorgan
Jefferies Analyst forecast on GB:0NZU
Benjamin Jackson CFA
Jefferies
Jefferies
kr505→kr320
Hold
4.95%
Upside
Downgraded
07/13/26
Zealand Pharma downgraded to Hold from Buy at JefferiesZealand Pharma downgraded to Hold from Buy at Jefferies
Berenberg Bank Analyst forecast on GB:0NZU
Kerry Holford
Berenberg Bank
Berenberg Bank
kr825→kr300
Hold
-1.61%
Downside
Downgraded
06/16/26
Berenberg Bank downgrades Zealand Pharma (ZLDPF) to a Hold
Deutsche Bank Analyst forecast on GB:0NZU
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
kr275→kr300
Hold
-1.61%
Downside
Reiterated
06/04/26
Zealand Pharma price target raised to DKK 300 from DKK 275 at Deutsche BankZealand Pharma price target raised to DKK 300 from DKK 275 at Deutsche Bank
UBS Analyst forecast on GB:0NZU
Xian Deng
UBS
UBS
kr730
Buy
139.42%
Upside
Reiterated
05/08/26
UBS Remains a Buy on Zealand Pharma (ZLDPF)
SEB Enskilda Analyst forecast on GB:0NZU
Thomas Bowers
SEB Enskilda
SEB Enskilda
kr380→kr475
Buy
55.79%
Upside
Upgraded
04/29/26
Zealand Pharma upgraded to Buy from Hold at SEB EquitiesZealand Pharma upgraded to Buy from Hold at SEB Equities
William Blair Analyst forecast on GB:0NZU
Andy Hsieh
William Blair
William Blair
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Market Perform from Outperform at William BlairZealand Pharma downgraded to Market Perform from Outperform at William Blair
Cantor Fitzgerald Analyst forecast on GB:0NZU
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Neutral from Overweight at Cantor FitzgeraldZealand Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
Exane BNP Paribas Analyst forecast on GB:0NZU
Kirsty Ross Stewart
Exane BNP Paribas
Exane BNP Paribas
kr275
Hold
-9.81%
Downside
Downgraded
03/06/26
Zealand Pharma downgraded to Neutral from Outperform at BNP ParibasZealand Pharma downgraded to Neutral from Outperform at BNP Paribas
Nordea Markets Analyst forecast on GB:0NZU
Martin Brenoe
Nordea Markets
Nordea Markets
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Hold from Buy at NordeaZealand Pharma downgraded to Hold from Buy at Nordea
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on GB:0NZU
Yihan Li
Barclays
Barclays
kr425→kr330
Hold
8.23%
Upside
Downgraded
09/08/26
Zealand Pharma downgraded to Equal Weight from Overweight at BarclaysZealand Pharma downgraded to Equal Weight from Overweight at Barclays
J.P. Morgan Analyst forecast on GB:0NZU
Sophia Graeff Buhl-Nielsen
J.P. Morgan
J.P. Morgan
kr460→kr435
Buy
42.67%
Upside
Reiterated
08/25/26
Zealand Pharma price target lowered to DKK 435 from DKK 460 at JPMorganZealand Pharma price target lowered to DKK 435 from DKK 460 at JPMorgan
Jefferies Analyst forecast on GB:0NZU
Benjamin Jackson CFA
Jefferies
Jefferies
kr505→kr320
Hold
4.95%
Upside
Downgraded
07/13/26
Zealand Pharma downgraded to Hold from Buy at JefferiesZealand Pharma downgraded to Hold from Buy at Jefferies
Berenberg Bank Analyst forecast on GB:0NZU
Kerry Holford
Berenberg Bank
Berenberg Bank
kr825→kr300
Hold
-1.61%
Downside
Downgraded
06/16/26
Berenberg Bank downgrades Zealand Pharma (ZLDPF) to a Hold
Deutsche Bank Analyst forecast on GB:0NZU
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
kr275→kr300
Hold
-1.61%
Downside
Reiterated
06/04/26
Zealand Pharma price target raised to DKK 300 from DKK 275 at Deutsche BankZealand Pharma price target raised to DKK 300 from DKK 275 at Deutsche Bank
UBS Analyst forecast on GB:0NZU
Xian Deng
UBS
UBS
kr730
Buy
139.42%
Upside
Reiterated
05/08/26
UBS Remains a Buy on Zealand Pharma (ZLDPF)
SEB Enskilda Analyst forecast on GB:0NZU
Thomas Bowers
SEB Enskilda
SEB Enskilda
kr380→kr475
Buy
55.79%
Upside
Upgraded
04/29/26
Zealand Pharma upgraded to Buy from Hold at SEB EquitiesZealand Pharma upgraded to Buy from Hold at SEB Equities
William Blair Analyst forecast on GB:0NZU
Andy Hsieh
William Blair
William Blair
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Market Perform from Outperform at William BlairZealand Pharma downgraded to Market Perform from Outperform at William Blair
Cantor Fitzgerald Analyst forecast on GB:0NZU
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Neutral from Overweight at Cantor FitzgeraldZealand Pharma downgraded to Neutral from Overweight at Cantor Fitzgerald
Exane BNP Paribas Analyst forecast on GB:0NZU
Kirsty Ross Stewart
Exane BNP Paribas
Exane BNP Paribas
kr275
Hold
-9.81%
Downside
Downgraded
03/06/26
Zealand Pharma downgraded to Neutral from Outperform at BNP ParibasZealand Pharma downgraded to Neutral from Outperform at BNP Paribas
Nordea Markets Analyst forecast on GB:0NZU
Martin Brenoe
Nordea Markets
Nordea Markets
―
Hold
―
Downgraded
03/06/26
Zealand Pharma downgraded to Hold from Buy at NordeaZealand Pharma downgraded to Hold from Buy at Nordea
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
JAZZJazz Pharmaceuticals
ONCBeOne Medicines
VKTXViking Therapeutics
HROWHarrow Health
KURAKura Oncology
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Zealand Pharma

3 Months
Xian DengUBS
Success Rate
1/3 ratings generated profit
33%
Average Return
-9.70%
Copying Xian Deng's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -9.70% per trade.
1 Year
Xian DengUBS
Success Rate
0/3 ratings generated profit
0%
Average Return
-25.00%
Copying Xian Deng's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -25.00% per trade.
2 Years
Xian DengUBS
Success Rate
0/3 ratings generated profit
0%
Average Return
-25.00%
Copying Xian Deng's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -25.00% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0NZU Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
6
4
1
0
0
Buy
1
1
1
1
1
Hold
6
2
3
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
7
5
4
3
In the current month, 0NZU has received 1 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. 0NZU average Analyst price target in the past 3 months is 346.25.
Each month's total comprises the sum of three months' worth of ratings.

0NZU Financial Forecast

0NZU Earnings Forecast

Next quarter’s earnings estimate for 0NZU is -kr9.63 with a range of -kr11.80 to -kr5.10. The previous quarter’s EPS was kr55.34. 0NZU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0NZU has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0NZU is -kr9.63 with a range of -kr11.80 to -kr5.10. The previous quarter’s EPS was kr55.34. 0NZU beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0NZU has Performed in-line its overall industry.

0NZU Sales Forecast

Next quarter’s sales forecast for 0NZU is kr101.96M with a range of kr0.00 to kr346.00M. The previous quarter’s sales results were kr4.49B. 0NZU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0NZU has Performed in-line its overall industry.
Next quarter’s sales forecast for 0NZU is kr101.96M with a range of kr0.00 to kr346.00M. The previous quarter’s sales results were kr4.49B. 0NZU beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0NZU has Performed in-line its overall industry.

0NZU Stock Forecast FAQ

What is GB:0NZU’s average 12-month price target, according to analysts?
Based on analyst ratings, Zealand Pharma’s 12-month average price target is 346.25.
    What is GB:0NZU’s upside potential, based on the analysts’ average price target?
    Zealand Pharma has 13.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Zealand Pharma a Buy, Sell or Hold?
          Zealand Pharma has a consensus rating of Hold, which is based on 1 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Zealand Pharma’s share price target?
            The average share price target for Zealand Pharma is 346.25. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is kr435.00 ,and the lowest forecast is kr300.00. The average share price target represents 13.56% Increase from the current price of kr304.9.
              What do analysts say about Zealand Pharma?
              Zealand Pharma’s analyst rating consensus is a Hold. This is based on the ratings of 4 Wall Streets Analysts.
                How can I buy shares of Zealand Pharma?
                To buy shares of GB:0NZU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.